U.S. Markets closed
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • Dow 30

    30,996.98
    -179.02 (-0.57%)
     
  • Nasdaq

    13,543.06
    +12.15 (+0.09%)
     
  • Russell 2000

    2,168.76
    +27.34 (+1.28%)
     
  • Crude Oil

    51.98
    -1.15 (-2.16%)
     
  • Gold

    1,855.50
    -10.40 (-0.56%)
     
  • Silver

    25.57
    -0.29 (-1.12%)
     
  • EUR/USD

    1.2171
    -0.0001 (-0.0122%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • Vix

    21.91
    +0.59 (+2.77%)
     
  • GBP/USD

    1.3685
    -0.0046 (-0.3339%)
     
  • USD/JPY

    103.7530
    +0.2480 (+0.2396%)
     
  • BTC-USD

    31,415.39
    -378.94 (-1.19%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.45 (-0.44%)
     

ROCE Insights For AcelRx Pharmaceuticals

Benzinga Insights
·1 min read

During Q3, AcelRx Pharmaceuticals's (NASDAQ:ACRX) reported sales totaled $1.37 million. Despite a 32.24% in earnings, the company posted a loss of $9.04 million. AcelRx Pharmaceuticals collected $2.92 million in revenue during Q2, but reported earnings showed a $6.83 million loss.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, AcelRx Pharmaceuticals posted an ROCE of 0.16%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on ACRX

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For AcelRx Pharmaceuticals, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Q3 Earnings Insight

AcelRx Pharmaceuticals reported Q3 earnings per share at $-0.1/share, which did not meet analyst predictions of $-0.08/share.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.